Editorial: Are we too high on medicinal cannabis in child psychiatry? Examining the evidence in Tourette syndrome
There has been renewed interest in elucidating the role of the endocannabinoid system on both brain development and psychological phenomena across the lifespan. In parallel to these efforts, the use of cannabis-related drugs for the treatment of psychiatric disorders in the community has increased considerably over the past several years. In an excellent research review article in JCPP, Tansey et al. provide a comprehensive overview of what the field of developmental psychopathology has learned about the endocannabinoid system. The purpose of this Editorial is to build upon the discussion around the current state of evidence for medicinal cannabis for psychiatric disorders, using Tourette syndrome and chronic tic disorders as an illustrative example.
Authors
- Luís C. Farhat (ORCID: https://orcid.org/0000-0002-3147-8344)
- Loren S. Hardeman
- Julian Koenig (ORCID: https://orcid.org/0000-0003-1009-9625)
- Michael H. Bloch (ORCID: https://orcid.org/0000-0003-0352-4080)
Institutions
- University of Cologne (DE)
- Yale Cancer Center (US)
- Yale University (US)
- University Hospital Cologne (DE)
- Morehouse School of Medicine (US)
Publication Details
- Journal
- Journal of Child Psychology and Psychiatry
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1111/jcpp.70075
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Neurocrine Biosciences
- Janssen Pharmaceuticals